Correlation Between Sartorius Stedim and Innate Pharma
Can any of the company-specific risk be diversified away by investing in both Sartorius Stedim and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sartorius Stedim and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sartorius Stedim Biotech and Innate Pharma, you can compare the effects of market volatilities on Sartorius Stedim and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sartorius Stedim with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sartorius Stedim and Innate Pharma.
Diversification Opportunities for Sartorius Stedim and Innate Pharma
0.02 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Sartorius and Innate is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Sartorius Stedim Biotech and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Sartorius Stedim is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sartorius Stedim Biotech are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Sartorius Stedim i.e., Sartorius Stedim and Innate Pharma go up and down completely randomly.
Pair Corralation between Sartorius Stedim and Innate Pharma
Assuming the 90 days trading horizon Sartorius Stedim Biotech is expected to under-perform the Innate Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Sartorius Stedim Biotech is 1.02 times less risky than Innate Pharma. The stock trades about -0.03 of its potential returns per unit of risk. The Innate Pharma is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 217.00 in Innate Pharma on August 26, 2024 and sell it today you would lose (64.00) from holding Innate Pharma or give up 29.49% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Sartorius Stedim Biotech vs. Innate Pharma
Performance |
| Timeline |
| Sartorius Stedim Biotech |
| Innate Pharma |
Sartorius Stedim and Innate Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Sartorius Stedim and Innate Pharma
The main advantage of trading using opposite Sartorius Stedim and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sartorius Stedim position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.| Sartorius Stedim vs. Eurofins Scientific SE | Sartorius Stedim vs. Teleperformance SE | Sartorius Stedim vs. Biomerieux SA | Sartorius Stedim vs. Dassault Systemes SE |
| Innate Pharma vs. Biomerieux SA | Innate Pharma vs. Eurofins Scientific SE | Innate Pharma vs. Sartorius Stedim Biotech | Innate Pharma vs. SEB SA |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |